* Integra Lifesciences Holdings – expects Q4 2016 gaap and
adjusted diluted EPS to be at or above mid-point of prior
guidance range of $0.32 to $0.35 and $0.50 to $0.53 respectively
The post BRIEF-Integra lifesciences sees FY 2017 adj shr $1.91 to $1.97 appeared first on NASDAQ.